In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Rebecca Guntern, chief commercial officer at Sandoz, for ...

AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, adding to its ...

Bayer's oral Factor XIa inhibitor asundexian is now under regulatory review by the EMA for secondary prevention of ischaemic ...

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart (SAR445088) in rare disease ...

The FDA has broadened the label for Eli Lilly's anti-IL-13 antibody Ebglyss, approving a maintenance regimen for atopic dermatitis (eczema) that involves just six injections a year. After a period of ...

Parabilis Medicines is expecting to raise around $670 million in its public offering, with another $75 million in a ...

According to Prostate Cancer UK, prostate cancer is the most common cancer in men: 1 in 8 men will get it and if you’re over 50, or you’re Black, or you have a family history of the disease, then your ...

A survey has shown that UK doctors think AI can help them save time and expand their capacity to care for patients, but three ...

Incyte has agreed to buy Star Therapeutics subsidiary Vega Therapeutics for $1.25 billion upfront, adding a late-stage drug ...

AI and connected data are reshaping feasibility and site selection across the clinical development lifecycle, allowing ...

EVERSANA has named Jen Norton as president of its Market Access & Value division, which helps life sciences companies secure ...

Data from the 310-subject VISTA trial revealed average weight reductions of up to 10.5% at 26 weeks and 11.8% at 36 weeks in ...